Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Magnetic therapy headset shows improved cognitive function and mood in people with long COVID (opens in a new tab)

medicalxpress.com · 2026-10-01

Short answerEvidenceSource

Short answer

Mixed

Mixed.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 3 supported
  • 2 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

Every claim we could check holds up. Three of five claims match the study. This overall rating is based only on the claims we could check. Two claims the study doesn't address.

  • 3 supported
  • 2 not covered
Open claim evidence
3
Source paper

Source layer

The 2 papers the story cites

Source study separated from background citations.

The research anchor for the report.

  • The study this story reportsmentioned without context

    Microtesla magnetic therapy for cognitive impairment in long COVID: a randomized pilot study

    Brain Communications · 2026

    Publisher (opens in a new tab)
  • The study this story reportsmentioned without context

    10.1093/braincomms/fcag364/8841135

    Publisher (opens in a new tab)
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5Not coveredIn this triple-blind pilot study, 30 participants with confirmed objective cognitive impairment from long COVID were randomized 2:1 to active or sham MMT and self-administered 15-minute sessions at home twice weekly for four weeks using a head-worn device.View evidenceHide evidence

As stated30 participants; 2:1 randomization; 15-minute sessions twice weekly for four weeks

Why this verdict

The abstract-level profile supports n=30, 2:1 randomization, active versus sham MMT, objective cognitive impairment after COVID-19, 15-minute at-home sessions twice weekly for 4 weeks, and a head-worn device. However, the supplied paper profile does not verify the claim that the study was triple-blind, so that part is not verifiable at abstract depth.

1

Study evidence

Feasibility was high: all participants who completed the study adhered to 100% of prescribed at-home MMT treatments and usability ratings were strong.100% adherence among study completers

“This is the first randomized controlled trial of MMT for long COVID cognitive impairment.”
Claim 2 of 5Not coveredThe researchers emphasize that the therapy remains investigational and does not establish the device as an approved treatment for long COVID; they say larger trials are needed to replicate the findings and assess durability and mechanism.View evidenceHide evidence

As statedlarger trials needed

Why this verdict

The supplied profile supports the caveat that findings are preliminary and require confirmation in larger, adequately powered trials, and that durability beyond Week 8 is not established. But the abstract-level profile does not verify regulatory framing such as the device not being an approved treatment, nor does it specifically document a researcher statement that mechanism must be assessed, so the full claim is not verifiable at this depth.

1

Study evidence

Feasibility was high: all participants who completed the study adhered to 100% of prescribed at-home MMT treatments and usability ratings were strong.100% adherence among study completers

“This is the first randomized controlled trial of MMT for long COVID cognitive impairment.”
2

Study evidence

Active MMT showed greater improvement than sham from baseline to Week 8 on WAIS Digit Span Sequencing.p = 0.026

“Cognitive function and self-reported mood and quality of life were exploratory outcomes assessed at baseline, Week 4 (post-treatment), and Week 8 (follow-up).”
Claim 3 of 5SupportedA new study led by researchers from the Icahn School of Medicine at Mount Sinai and published in Brain Communications found that a transcranial low-amplitude magnetic field intervention delivered twice weekly into the brain through a noninvasive headset was associated with improvements in several measures of cognitive function and emotional well-being in people experiencing cognitive impairment associated with long COVID.View evidenceHide evidence

As statedtwice weekly; improvements in several measures

Why this verdict

The abstract-level profile supports the study design, at-home head-worn MMT dosing schedule, long COVID cognitive-impairment population, and exploratory between-group improvements favoring active MMT on selected cognitive tests and SF-36 emotional well-being. The story frames the efficacy finding associationally and hedges it, which fits the preliminary pilot evidence.

1

Study evidence

Feasibility was high: all participants who completed the study adhered to 100% of prescribed at-home MMT treatments and usability ratings were strong.100% adherence among study completers

“This is the first randomized controlled trial of MMT for long COVID cognitive impairment.”
2

Study evidence

Active MMT showed greater improvement than sham from baseline to Week 8 on WAIS Digit Span Sequencing.p = 0.026

“Cognitive function and self-reported mood and quality of life were exploratory outcomes assessed at baseline, Week 4 (post-treatment), and Week 8 (follow-up).”
Claim 4 of 5SupportedThe improvements seen among patients who received the therapy continued after the treatment period ended, providing early evidence that noninvasive biophysical approaches may warrant further study as potential treatments for persistent neurological symptoms of long COVID.View evidenceHide evidence

As statedcontinued after the treatment period ended

Why this verdict

The profile reports exploratory outcomes assessed at Week 8 follow-up after the 4-week treatment period, with selected cognitive and emotional well-being measures favoring active MMT. The claim is acceptable as a hedged statement about early evidence warranting further study, provided it is understood as limited to Week 8 and not durability beyond that follow-up.

1

Study evidence

Active MMT showed greater improvement than sham from baseline to Week 8 on WAIS Digit Span Sequencing.p = 0.026

“Cognitive function and self-reported mood and quality of life were exploratory outcomes assessed at baseline, Week 4 (post-treatment), and Week 8 (follow-up).”
Claim 5 of 5SupportedParticipants receiving the active treatment demonstrated improvements in working memory, verbal learning, processing speed and emotional well-being compared with those receiving the sham intervention, and the investigators observed continued improvement in several measures at eight weeks of follow-up.View evidenceHide evidence

As statedimprovements in working memory, verbal learning, processing speed and emotional well-being; continued improvement at week eight

Why this verdict

The profile supports nominally significant exploratory improvements versus sham on selected measures corresponding to working memory/sequencing, verbal learning/recall, a processing-speed-related color-naming measure, and SF-36 emotional well-being at Week 8. The rationale should be qualified by the paper’s caveats: these were exploratory outcomes in a small pilot trial, and other attention, processing speed, and executive-function measures did not differ significantly.

1

Study evidence

Active MMT showed greater improvement than sham from baseline to Week 8 on WAIS Digit Span Sequencing.p = 0.026

“Cognitive function and self-reported mood and quality of life were exploratory outcomes assessed at baseline, Week 4 (post-treatment), and Week 8 (follow-up).”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • The paper’s primary contribution was feasibility of at-home MMT self-administration, including adherence/completion/usability, not definitive efficacy.

    The story mentions that feasibility and safety were assessed, but the presented claims focus mainly on clinical improvement and do not convey that feasibility was the primary endpoint or that high adherence/usability among completers was a central paper result.

    From Randomized sham-controlled at-home device feasibility trial (pilot)

  • Safety/tolerability was a secondary objective, and the abstract reports no device-related adverse events.

    The story caveats mention that safety was assessed and that the therapy remains investigational, but the presented claims do not report the paper’s specific safety finding of no device-related adverse events or the limited nature of harms evidence in a small pilot.

    From randomized sham-controlled pilot trial (at-home device intervention)

  • Most cognitive measures did not differ significantly between active and sham groups.

    The story says there were improvements in several measures, but the supplied presentation does not mention the counterbalancing result that other attention, processing speed, and executive-function measures were not significantly different. This omission matters because it limits interpretation of the breadth of cognitive benefit.

    From Randomized sham-controlled pilot trial (2:1 randomization)

3 things the story did carry across
  • Exploratory efficacy signals favored active MMT on selected cognitive tests and SF-36 emotional well-being at Week 8.
  • The study was small, with n=30 and 2:1 randomization, limiting power and precision.
  • Follow-up only extended to Week 8, so durability beyond that period is unknown.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

3

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoEvaluate feasibility of at-home Microtesla Magnetic Therapy (MMT) self-administration in long COVID patients with objective cognitive impairment (adherence/completion/usability).Randomized sham-controlled at-home device feasibility trial (pilot)Expand

In plain English

Randomized 2:1 pilot trial (n=30) testing at-home self-administered Microtesla Magnetic Therapy (MMT) versus sham in people with objective cognitive impairment after COVID-19. Primary outcome was feasibility (≥80% of prescribed treatments plus completion of study visits); feasibility was high with all study completers adhering to 100% of treatments and strong usability ratings. Safety (secondary) showed no device-related adverse events. Findings are preliminary and require confirmation in larger trials.

Key findings

  • Feasibility was high: all participants who completed the study adhered to 100% of prescribed at-home MMT treatments and usability ratings were strong.100% adherence among study completers
  • No device-related adverse events were reported during the trial.
“This is the first randomized controlled trial of MMT for long COVID cognitive impairment.”
What this piece can’t prove
  • Pilot randomized trial with small total sample (n=30); limited statistical power.
  • Feasibility adherence result is reported for study completers; the abstract does not specify the number of participants who completed the study versus randomized.
  • Results are preliminary and the authors state they require confirmation in larger, adequately powered trials.
2human in vivoEvaluate safety/tolerability of at-home MMT (adverse events/device-related events).randomized sham-controlled pilot trial (at-home device intervention)Expand

In plain English

Randomized, sham-controlled pilot trial (n=30, randomized 2:1 active:sham) of at-home Microtesla Magnetic Therapy (head-worn device delivering a nonthermal radiofrequency magnetic field) administered 15 minutes twice weekly for 4 weeks with remote monitoring. Safety/tolerability was a secondary objective and was assessed using adverse event reporting; the abstract reports that no device-related adverse events occurred and that the intervention was well tolerated.

Key findings

  • No device-related adverse events occurred during the intervention and follow-up as reported in the abstract.
  • The intervention was reported as well tolerated with strong usability ratings and complete adherence among study completers.
“We evaluated the feasibility (primary) and safety (secondary) of at-home MMT”
What this piece can’t prove
  • Small pilot sample (n=30) and brief follow-up (to Week 8) limit detection of rare or late-emerging harms.
  • Unclear whether standardized harms ascertainment procedures (e.g., grading scale, blinded adjudication) were used based on abstract text.
  • Device-related adverse events explicitly reported as absent, but absence of other adverse event information prevents fuller appraisal of overall harms profile.

1 further detail could not be confirmed from the summary.

3human in vivoExplore preliminary efficacy signals of MMT vs sham on objective cognitive outcomes and patient-reported mood/quality of life over baseline, Week 4, and Week 8.Randomized sham-controlled pilot trial (2:1 randomization)Expand

In plain English

In a randomized (2:1) sham-controlled pilot trial of at-home Microtesla Magnetic Therapy (MMT) for cognitive impairment after COVID-19 (n=30), exploratory cognitive and patient-reported outcomes were assessed at baseline, Week 4 (post-treatment), and Week 8 (follow-up). Between-group comparisons and linear mixed-effects models were used. Compared with sham, active MMT showed nominally significant greater improvement from baseline to Week 8 on selected objective cognitive tests (WAIS Digit Span Sequencing, HVLT‑R Total Recall, D‑KEFS Color Naming) and on SF-36 Emotional Well-Being. Anxiety decreased more with active treatment in a week × treatment linear mixed-effects interaction, although the between-group change score comparison for anxiety did not reach conventional significance. Other measures of attention, processing speed, and executive function did not differ between groups. Findings are exploratory and reported as preliminary signals requiring confirmation in larger, adequately powered trials.

Key findings

  • Active MMT showed greater improvement than sham from baseline to Week 8 on WAIS Digit Span Sequencing.p = 0.026
  • Active MMT showed greater improvement than sham from baseline to Week 8 on verbal learning/recall (HVLT‑R Total Recall).p = 0.044
“Cognitive function and self-reported mood and quality of life were exploratory outcomes assessed at baseline, Week 4 (post-treatment), and Week 8 (follow-up).”
What this piece can’t prove
  • Small sample size (n=30) and 2:1 randomization limit statistical power and precision of effect estimates.
  • Short follow-up (to Week 8) in a pilot trial—durability of effects beyond this period not assessed.
  • Findings are preliminary and require confirmation in larger, adequately powered randomized trials.

1 further detail could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Open the paper in Tessa

Microtesla magnetic therapy for cognitive impairment in long COVID: a randomized pilot study

Brain Communications · 2026

Source record (opens in a new tab)

Why this one

Near certain

NewsLink found the paper. Tessa is where you inspect it deeply.

Papers considered

The selected paper, plus nearby candidates.

Crossref, PubMed, Europe PMC · 15 candidate papers

Selected

Microtesla magnetic therapy for cognitive impairment in long COVID: a randomized pilot study

Brain Communications · 2026 · Crossref

Source (opens in a new tab)

And 9 more candidates considered.